Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis

NCT02428231 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02428231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2015
Completion date
January 31, 2016
Enrollment
62 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis